CytomX Therapeutics (CTMX) Interest & Investment Income (2014 - 2026)

CytomX Therapeutics' Interest & Investment Income history runs 13 years deep, the most recent figure standing at $1.5 million for Q1 2026.

• Quarterly Interest & Investment Income rose 56.02% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (down 2.65% YoY) and the FY2025 annual result came in at $5.2 million, down 27.05% from the prior year.
• Interest & Investment Income was $1.5 million for Q1 2026 at CytomX Therapeutics, up from $1.5 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $2.7 million in Q3 2023 and bottomed at $68000.0 in Q1 2022.
• A 5-year average of $1.5 million and a median of $1.5 million in 2026 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2023 — Interest & Investment Income surged 3322.06% — and 2025, when it slumped 56.47%.
• CytomX Therapeutics' Interest & Investment Income stood at $732000.0 in 2022, then soared by 241.94% to $2.5 million in 2023, then tumbled by 48.94% to $1.3 million in 2024, then increased by 15.88% to $1.5 million in 2025, then grew by 0.61% to $1.5 million in 2026.
• Business Quant data shows CTMX's Interest & Investment Income at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.